Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F-627 vs filgrastim for prevention of chemotherapy-induced neutropenia in breast cancer
CTR20170705Phase 3Completed
- Sponsor
- Generon
- Start
- Jan 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of efbemalenograstim alfa in breast cancer, chemotherapy-induced neutropenia (CIN), sponsored by Generon. Started Jan 2018; status: completed.
02
Drugs
efbemalenograstim alfa
03
Conditions
breast cancerchemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on CTR20170705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170705.